A trial of clenbuterol in bronchial asthma.
Open Access
- 1 December 1977
- Vol. 32 (6) , 717-719
- https://doi.org/10.1136/thx.32.6.717
Abstract
Clenbuterol is a beta 2-sympathomimetic bronchodilator. In a double-blind cross-over trial in 19 asthmatic patients with reversible airways obstruction, oral administration of both clenbuterol (40 microgram) and salbutamol (4 mg) caused significantly greater increased in peak expiratory flow rate (PEFR) than placebo, that of clenbuterol lasting longer. The patients' subjective assessment also suggested the relief of their symptoms by the active drugs. Side-effects were minimal.This publication has 5 references indexed in Scilit:
- The bronchodilator effect of NAB 365.Published by Wiley ,1977
- [Single and multiple applications and metabolite pattern of clenbuterol in man (author's transl)].1976
- Double-blind cross-over comparison of clenbuterol and salbutamol tablets in asthmatic out-patientsEuropean Journal of Clinical Pharmacology, 1975
- An economical method of comparing inhaled bronchodilators in reversible diffuse airways obstruction: With special reference to a -2 stimulant--salmefamolThorax, 1974
- Non-Parametric Statistics for the Behavioral Sciences.Economica, 1957